249 related articles for article (PubMed ID: 23992266)
1. Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease.
Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Shimizu K; Sato S
Int J Rheum Dis; 2013 Aug; 16(4):442-7. PubMed ID: 23992266
[TBL] [Abstract][Full Text] [Related]
2. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases.
Kurkijärvi R; Adams DH; Leino R; Möttönen T; Jalkanen S; Salmi M
J Immunol; 1998 Aug; 161(3):1549-57. PubMed ID: 9686623
[TBL] [Abstract][Full Text] [Related]
3. Serum CCL23 levels are increased in patients with systemic sclerosis.
Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Asano Y; Kadono T; Sato S
Arch Dermatol Res; 2011 Jan; 303(1):29-34. PubMed ID: 20824279
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
5. Serum vascular adhesion protein-1 correlates with vascular endothelial growth factor in patients with type II diabetes.
Yoshikawa N; Noda K; Shinoda H; Uchida A; Ozawa Y; Tsubota K; Mashima Y; Ishida S
J Diabetes Complications; 2013; 27(2):162-6. PubMed ID: 23062326
[TBL] [Abstract][Full Text] [Related]
6. Neuron specific enolase concentration is increased in serum and decreased in platelets of patients with active systemic sclerosis.
Massabki PS; Silva NP; Lourenço DM; Andrade LE
J Rheumatol; 2003 Dec; 30(12):2606-12. PubMed ID: 14719201
[TBL] [Abstract][Full Text] [Related]
7. Soluble vascular adhesion protein-1: decreased activity in the plasma of trauma victims and predictive marker for severity of traumatic brain injury.
Lin Z; Han M; Li H; Luo H; Zhang Y; Luo W
Clin Chim Acta; 2011 Aug; 412(17-18):1678-82. PubMed ID: 21645499
[TBL] [Abstract][Full Text] [Related]
8. Elevated circulating CD40L concentrations in patients with systemic sclerosis.
Komura K; Sato S; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2004 Mar; 31(3):514-9. PubMed ID: 14994397
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis.
Jinnin M; Makino T; Kajihara I; Honda N; Makino K; Ogata A; Ihn H
Br J Dermatol; 2010 Apr; 162(4):751-8. PubMed ID: 19886888
[TBL] [Abstract][Full Text] [Related]
10. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis.
Yanaba K; Yoshizaki A; Asano Y; Kadono T; Sato S
J Rheumatol; 2011 Oct; 38(10):2193-7. PubMed ID: 21807780
[TBL] [Abstract][Full Text] [Related]
12. Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis.
Toiyama Y; Miki C; Inoue Y; Kawamoto A; Kusunoki M
J Surg Oncol; 2009 May; 99(6):368-72. PubMed ID: 19204971
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble vascular adhesion protein-1 is a valuable prognostic marker in gastric cancer.
Yasuda H; Toiyama Y; Ohi M; Mohri Y; Miki C; Kusunoki M
J Surg Oncol; 2011 Jun; 103(7):695-9. PubMed ID: 21308684
[TBL] [Abstract][Full Text] [Related]
14. Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis.
Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
Br J Dermatol; 2012 Sep; 167(3):542-7. PubMed ID: 22540233
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis.
Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
Arch Dermatol Res; 2012 Apr; 304(3):203-8. PubMed ID: 22139405
[TBL] [Abstract][Full Text] [Related]
16. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis.
Yamaguchi Y; Ono J; Masuoka M; Ohta S; Izuhara K; Ikezawa Z; Aihara M; Takahashi K
Br J Dermatol; 2013 Apr; 168(4):717-25. PubMed ID: 23110679
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
18. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis.
Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):37-42. PubMed ID: 22112232
[TBL] [Abstract][Full Text] [Related]
19. Elevation of serum lymphotactin levels in patients with systemic sclerosis.
Muroi E; Ogawa F; Shimizu K; Komura K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 May; 35(5):834-8. PubMed ID: 18322986
[TBL] [Abstract][Full Text] [Related]
20. Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk.
De Luca G; Bosello SL; Berardi G; Rucco M; Canestrari G; Correra M; Mirone L; Forni F; Di Mario C; Danza FM; Pirronti T; Ferraccioli G
Rheumatology (Oxford); 2015 Nov; 54(11):1991-9. PubMed ID: 26106211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
